Free shipping over €250 · Tracked, discreet delivery in Europe
UU library
Every peptide, mapped to the body.
160 compounds, from approved medicines to early research molecules. Each one filed by the system research looks at, with its regulatory status and the strength of the evidence behind it.
- Compounds
- 160
- Research summaries
- 39
- At UU
- 56
- Approved medicine71
Approved as a medicine by the FDA or the EMA for at least one indication. Approval covers the named indication and formulation only.
- In clinical trials19
In human clinical trials and not yet approved by the FDA or the EMA. Results to date are from trial populations under medical supervision.
- Research compound53
Not approved as a medicine by the FDA or the EMA. Some are registered in individual countries. Supplied for laboratory research only.
- Cosmetic ingredient17
Used as a topical cosmetic ingredient. Cosmetic use is not a medicinal approval, and most evidence comes from manufacturer and small panel studies.
Reviewed October 2026
In the UU catalog
Researched, batch-tested, ready to ship.
Compounds UU carries that have a full research summary in the library.
14 compounds · Heart & blood
Heart & blood14
Vascular peptides, anticoagulants and the mitochondrial peptides studied in cardiac research.
- ApprovedAt UU
Semaglutide
Ozempic · Wegovy
GLP-1 receptor agonist
A long-acting GLP-1 analogue approved for type 2 diabetes and chronic weight management, in weekly injected and daily oral forms.
Human trialsShop - Approved
Angiotensin II
Giapreza
Vasoconstrictor
A synthetic form of the body's own octapeptide vasoconstrictor. Approved to raise blood pressure in septic and distributive shock.
Summary pending - Approved
Bivalirudin
Angiomax
Direct thrombin inhibitor
A 20-residue synthetic thrombin inhibitor. Approved as an anticoagulant during coronary procedures.
Summary pending - In trials
Enlicitide
MK-0616
Oral macrocyclic PCSK9 inhibitor
An oral macrocyclic peptide that blocks PCSK9. In Phase 3 trials for lowering LDL cholesterol.
Summary pending - Approved
Eptifibatide
Integrilin
Glycoprotein IIb/IIIa inhibitor
A cyclic heptapeptide based on rattlesnake venom. Approved to block platelet clumping in acute coronary syndromes.
Summary pending - Approved
Motixafortide
Aphexda
CXCR4 antagonist
A cyclic peptide that blocks CXCR4. Approved to mobilise stem cells for collection before transplant in multiple myeloma.
Summary pending - Approved
Nesiritide
Natrecor
B-type natriuretic peptide
Recombinant B-type natriuretic peptide, approved by the FDA for acutely decompensated heart failure and now rarely used.
Summary pending - Approved
Pegcetacoplan
Empaveli · Aspaveli
Complement C3 inhibitor
A pegylated cyclic peptide that blocks complement C3. Approved for paroxysmal nocturnal haemoglobinuria and geographic atrophy.
Summary pending - In trials
Rusfertide
Hepcidin mimetic
A synthetic mimic of the iron hormone hepcidin. In Phase 3 trials for polycythaemia vera.
Summary pending - Approved
Terlipressin
Terlivaz
Vasopressin analogue
A vasopressin prodrug approved for hepatorenal syndrome, and in Europe for bleeding oesophageal varices.
Summary pending - Approved
Vasopressin
Vasostrict
Pituitary hormone
The nine-residue antidiuretic hormone. Approved to raise blood pressure in vasodilatory shock.
Summary pending
The UU library is an educational reference. It is not medical advice, does not make a health claim, and does not tell anyone how to use a compound. UU products are sold for laboratory research use only and are not for human consumption. Regulatory status changes: confirm it with the relevant authority before relying on it.